There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Liquidia Technologies Inc (LQDA) and Bellerophon (BLPH) with bullish sentiments.
Liquidia Technologies Inc (LQDA)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Liquidia Technologies Inc today and set a price target of $49. The company’s shares opened today at $10.93, close to its 52-week low of $10.05.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -6.4% and a 39.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Liquidia Technologies Inc is a Moderate Buy with an average price target of $49.
See today’s analyst top recommended stocks >>
Bellerophon (BLPH)
In a report released today, Caroline Palomeque from Maxim Group maintained a Buy rating on Bellerophon, with a price target of $3. The company’s shares opened today at $0.73, close to its 52-week low of $0.47.
Palomeque said:
“The FDA agreed to let the Phase 2b trial of INOpulse be amended to a Phase 2/3 trial with Cohort 3 becoming the pivotal Phase 3 portion of the study. and initiation of Cohort 3 to begin in 2H19.”
According to TipRanks.com, Palomeque ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.5% and a 44.0% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as VistaGen Therapeutics, AzurRx BioPharma Inc, and Oxford BioMedica plc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bellerophon with a $3 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
